NIHR Oxford Biomedical Research Centre

Enabling translational research through partnership

MENUMENU
  • About
    • About the NIHR Oxford Biomedical Research Centre
    • A Guide to What We Do
    • Activities during COVID-19
    • Strategic Partnership Board
    • Steering Committee
    • Promoting Equality, Diversity and Inclusion in Research
    • Current Vacancies
    • Contact Us
    • Stay in Touch
  • Research
        • OUR 20 RESEARCH THEMES

        • Antimicrobial Resistance and Modernising Microbiology
        • Cardiovascular
        • Clinical Informatics and Big Data
        • Diabetes and Metabolism
        • Gastroenterology and Mucosal Immunity
        • Genomic Medicine
        • Haematology and Stem Cells
        • Imaging
        • Molecular Diagnostics
        • Multi-Modal Cancer Therapies
        • Multi-Morbidity and Long-Term Conditions
        • Musculoskeletal
        • Neurological Conditions
        • Obesity, Diet and Lifestyle
        • Partnerships for Health, Wealth and Innovation
        • Respiratory
        • Stroke and Vascular Dementia
        • Surgical Innovation and Evaluation
        • Technology and Digital Health
        • Vaccines for Emerging and Endemic Diseases
        • Oxford Biomedical Research Centre activities during COVID-19
  • Patient & Public Involvement
    • Getting involved with research
    • Researcher Guidance
    • Post an opportunity for patient and public involvement
  • Training Hub
    • Training Hub Overview
    • Clinical Academic Pathway
    • Internships
    • Preparatory Research Fellowships
    • Senior Research Fellowships
    • Research Training Bursaries
    • Doctoral Awards
    • Post-Doctoral Awards
    • Other funding
    • Leadership Training
    • Useful Links
    • Training and Education Resources
    • Upcoming Training Events & Courses
  • Industry
    • Collaborate with Oxford BRC
    • What Can We Do For Your Organisation?
    • Who Do We Work With?
    • IP and Licensing
    • Contacts for Industry
  • Videos
  • News
  • Events

News

You are here: Home > COVID-19 > Common heart medication does not increase risk of COVID-19 hospitalisation

Common heart medication does not increase risk of COVID-19 hospitalisation

10 August 2020 · Listed under Cardiovascular, Clinical Informatics and Big Data, COVID-19, Technology and Digital Health

A study by Oxford researchers, supported by the NIHR Oxford Biomedical Research Centre (BRC), found that ACE inhibitors and ARBs – both common treatments for high blood pressure and heart failure – are not generally linked to an increased risk of severe COVID-19 disease or an increased likelihood of being admitted to intensive care.

Photo by Christine Sandu on Unsplash

However, the researchers did find higher risk of severe COVID-19 disease for some BAME groups, especially Black African patients taking ACE inhibitors. The study was published as an open access paper in the BMJ Heart journal.

Angiotensive enzyme (ACE) inhibitor and angiotensin receptor blocker (ARB) are common heart medications to treat heart failure and high blood pressure, and are often prescribed following a heart attack. 

Prof Julia Hippisley-Cox of the Nuffield Department of Primary Care Health Sciences and Prof Peter Watkinson, the Oxford BRC’s Joint Theme Lead for Technology and Digital Health led the study.

Prof Watkinson said: “There had been some uncertainty about the relationship between these common heart medications and COVID-19 disease. We set out to find out if patients prescribed these drugs had altered risks of contracting severe COVID-19 disease and of being admitted to ICU.”

This large, population-based study matched the records of 1,205 UK general practices contributing to the QResearch database with data from Public Health England and from the Intensive Care National Audit and Research Centre (ICNARC).

Prof Hippisley-Cox said: “We examined the drug histories of around 20% of all patients in England who tested positive for coronavirus, to see if there was an independent association between ACE inhibitor or ARB drug prescription and severe COVID-19 disease susceptibility and progression.

“We found overall ACE inhibitors and ARBs were associated with a reduced risk of severe COVID-19 disease, but not associated with the risk of needing admission to an Intensive Care Unit. However, our findings varied by ethnicity. For Black African groups, taking ACE inhibitors was associated with an increased risk of severe COVID-19 disease.”

She added: “This variation between different ethnic groups raises the possibility of specific effects of these drugs on susceptibility to COVID-19 among certain groups and on the severity of the disease, and this deserves further study.”

← Oxford University and ZOE partner on COVID-19 treatment trials
Paper outlines management of post-acute COVID-19 in primary care →

News

  • BRC study outlines researchers training needs and barriers 20 May 2022
  • Three new Blood and Transplant Research Units created in Oxford 18 May 2022
  • Oxford’s medical, health and life sciences research excellence recognised 12 May 2022
See full news archive

News Categories

Month Archives

Subscribe to the Oxford BRC Newsletter

Keep informed about the work of the Oxford BRC by subscribing to our Mailchimp e-newsletter. It is produced several times a year and delivers news and information about upcoming events straight to your inbox.

Subscribe Now

Oxford BRC on Social Media

  • Facebook
  • LinkedIn
  • Twitter
  • YouTube

Feedback

We’d love to hear your feedback. Please contact us at obrcenquiries@ouh.nhs.uk

  • Sitemap
  • Data Control and Privacy
  • Accessibility
  • Our Partners
  • Disclaimer
  • Contact

Copyright © 2022 NIHR Oxford Biomedical Research Centre